RaQualia Pharma (TSE:4579) Current Deferred Taxes Liabilities: 円 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4579 RaQualia Pharma Inc TSE:4579
62 GF Score
Price 円594.00
GF Value 円821.19
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is RaQualia Pharma Current Deferred Taxes Liabilities?

RaQualia Pharma TSE:4579 +2.06% 62 Current Deferred Taxes Liabilities is 円 Mil as of Jun. 2026. GuruFocus rates TSE:4579 with a GF Score™ of 62/100 and a GF Value™ of 円821.19 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Current Deferred Taxes Liabilities represent future tax liabilities, resulting from temporary differences between book (accounting) value of assets and liabilities and their tax value, or timing differences between the recognition of gains and losses in financial statements and their recognition in a tax computation. Deferred tax liabilities generally arise where tax relief is provided in advance of an accounting expense, or income is accrued but not taxed until received.

RaQualia Pharma's current deferred tax liabilities for the quarter that ended in Jun. 2026 was 円 Mil.

RaQualia Pharma Current Deferred Taxes Liabilities Related Terms

RaQualia Pharma Current Deferred Taxes Liabilities Historical Data

* Premium members only.

The historical data trend for RaQualia Pharma's Current Deferred Taxes Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RaQualia Pharma Current Deferred Taxes Liabilities Chart

RaQualia Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Taxes Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

RaQualia Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Taxes Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -
TSE:4579
62GF Score
RaQualia Pharma Inc TSE:4579
Current Deferred Taxes Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Taxes Liabilities of 円 Mil mean?
RaQualia Pharma (TSE:4579) has a Current Deferred Taxes Liabilities of 円 Mil as of Jun. 2026. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on RaQualia Pharma and its competitors.
Is RaQualia Pharma's Current Deferred Taxes Liabilities too high?
RaQualia Pharma's current Current Deferred Taxes Liabilities is 円 Mil. Overall, RaQualia Pharma has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does RaQualia Pharma's Current Deferred Taxes Liabilities compare to VRTX and REGN?
RaQualia Pharma's Current Deferred Taxes Liabilities of 円 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Taxes Liabilities for a Biotechnology company?
A good Current Deferred Taxes Liabilities depends on the Biotechnology industry context. However, Current Deferred Taxes Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Taxes Liabilities mean?
A high Current Deferred Taxes Liabilities can signal that a stock is expensive relative to its fundamentals. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on RaQualia Pharma and its competitors. RaQualia Pharma's current Current Deferred Taxes Liabilities is 円 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaQualia Pharma stock overvalued right now?
Based on GuruFocus' analysis, RaQualia Pharma (TSE:4579) is currently considered Modestly Undervalued. The stock's GF Value™ is 円821.19, compared to a current price of 円594.00 — trading 27.7% below its estimated fair value. The current Current Deferred Taxes Liabilities is 円 Mil. RaQualia Pharma's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Taxes Liabilities calculated?
Current Deferred Taxes Liabilities is calculated from a company's financial statements. For RaQualia Pharma (TSE:4579), the current Current Deferred Taxes Liabilities is 円 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RaQualia Pharma (TSE:4579) Overvalued in 2026?

Based on GuruFocus' analysis, RaQualia Pharma stock appears to be undervalued. The current stock price of 円594.00 is trading 27.7% below its estimated GF Value™ of 円821.19. GuruFocus considers RaQualia Pharma to be Modestly Undervalued.

Key valuation signals for TSE:4579:

  • Current Deferred Taxes Liabilities: 円 Mil
  • GF Value™: 円821.19 vs. price of 円594.00 (27.7% below fair value)
  • GF Score™: 62/100 with 2 warning signs

No single metric tells the full story. See the TSE:4579 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

RaQualia Pharma Business Description

Address 1-21-19 Meieki Minami, Nakamura-ku, Nagoya, JPN, 470-2341
RaQualia Pharma Inc operates as a research and development-centered biotechnology company, generating revenue by creating the seeds for novel medicine and licensing them to pharmaceutical companies. The company manages the Sales and licensing of intellectual property for fundamental technologies related to pharmaceutical compounds and candidate compounds for clinical development. Its product portfolio includes, Tegoprazan (K-CAB), Galliprant and Elura both under Veterinary Medicines. The pipeline products include Potassium-Competitive Acid Blocker, Ghrelin Receptor Agonist, TRPM8 Blocker and 5-HT4 Agonist studied under different phases of development.
62GF Score

Get the complete analysis for TSE:4579

Current Deferred Taxes Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円594.00
Price
円821.19
GF Value